Nicorette Mini Return Provides More Retail Therapy For Glaxo Consumer
This article was originally published in The Tan Sheet
Executive Summary
Following the February launch of its Flonase Allergy Relief OTC switch and the return of alli following a recall, Glaxo adds another momentum driver before the pending launch of its consumer product JV with Novartis by returning Nicorette minis as an OTC revenue source.
You may also be interested in...
Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.